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Background: Only protein diet has been used successfully to prevent loss of lean body mass first in post-surgical
and then in obese patients. We studied overweight and obese patients receiving short treatments of an exclusively
protein-based nutritional solution as 24-hour enteral infusion.
Methods: 19,036 patients (age 44.3 ± 13, M:F = 2:5) with an initial body mass index of 36.5 ± 7.1 underwent
10-day cycles of enteral nutrition through a fine nasogastric tube. The nutritional solution consisted solely of
50–65 g of proteins, plus vitamins and electrolytes. The 24-hour infusion was controlled with a small portable
pump. Before and after each 10-day cycle body composition was checked with a Handy 3000 impedance analyzer.
At the onset of treatment, average fat mass was 40.9 ± 12.8 kg while body cell mass was 42.7 ± 7.2 kg in males and
27.4 ± 4.6 kg in females.
Results: After an average of 2.5 cycles the patients lost 10.2 ± 7.0 kg of body weight, 5.8 ± 5.5 kg of fat mass and
2.2 ± 3.3 kg of body cell mass. No significant adverse effects were recorded except asthenia and constipation which
were easily controlled with therapy. Long-term results were obtained from 15,444 patients and after an average of
362 ± 296 days we found a mean weight regain of 15.4%.
Conclusion: Ketogenic Enteral Nutrition treatment of over 19,000 patients induced a rapid 10% weight loss, 57% of
which was Fat Mass. No significant adverse effects were found. The treatment is safe, fast, inexpensive and has
good one-year results for weight maintenance.
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Obesity is a 21st century epidemic, and its relentless
spreading is due to many different reasons. One reason
is that the classic treatment, a long term hypocaloric
diet, is unsuited to the spirit of our century that always
aims for fast results. Dieters want instant weight loss
and do not want to lose “only” a few pounds each week.
Finding a fast and safe weight loss treatment could be
the crucial battle to win in the war on obesity.
We know that weight loss is a consequence of negative
caloric balance and the more negative the caloric bal-
ance the more rapid the weight reduction will be. Given* Correspondence: cappello.g@in.it
Clinical Nutrition Service of the Department of Surgery Paride Stefanini,
University of Rome La Sapienza, Rome, Italy
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reproduction in any medium, provided the orthis logic, total fasting should be the most rapid way to
lose weight but it is impractical for two reasons:
1. It would cause extreme hunger [1].
2. It would entail loss of lean body mass (LBM), which
can be unsafe for the patient [2]. Total fasting also
causes neutropenia [3], lowers renal creatinine
clearence [4] and increases levels of serum bilirubin
[5]. The total nitrogen loss after 3 to 4 weeks of total
starvation would be approximately 200 g,
corresponding to 1,250 g of protein and equivalent to
a loss of some 6 kg of muscle tissue [6,7]. The obese
patient will lose body mass in the wrong places
(e.g. thighs, limbs, chest) generating a cachectic
appearance. Furthermore he will rapidly regain all
the lost weight as the body works to rebuild its LBMal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Cappello et al. Nutrition & Metabolism 2012, 9:96 Page 2 of 7
http://www.nutritionandmetabolism.com/content/9/1/96[8]. Thus, optimal weight loss must be achieved
through reducing fat mass.
An important experiment by Blackburn and colleagues
in 1973 [9] demonstrated that, during fasting, a continu-
ous intravenous infusion of an amino acid solution could
greatly reduce protein loss. Because the treatment was
able to totally prevent loss of LBM during fasting, it was
said to have a protein sparing (PS) effect. Blackburn
explained the PS effect through the action of insulin, the
main regulator of energetic fuels, by reasoning that the
infusion of amino acids during fasting reduced insulin
levels and therefore prevented muscle catabolism while
at the same time a strong lipolytic effect was promoted
with high serum ketone bodies (KB) [10]. Increased
serum KB will not harm the patient because high serum
KB will eventually increase insulin secretion, modulating
the lipolytic effect [11,12]. Furthermore high serum KB
will reduce or eliminate hunger [13,14].
Blackburn et al. immediately realized the importance
of the PS effect for the treatment of obesity. They
invented a very low calorie protein diet [15], the protein
sparing modified fast (PSMF), but their subsequent stud-
ies on obese patients were based on an oral protein diet
which had two main drawbacks: (1) glucose intake could
not be reduced to zero and (2) protein intake stopped
during the night. Normally overnight fasting does not
entail muscle catabolism because hepatic glycogen sus-
tains the patient’s energy requirement [16-18], but after
one day of a high protein diet glycogen deposits are
greatly reduced [16] and overnight fasting will entail
muscle catabolism. As a result the lipolytic effect of the
PSMF is reduced and many weeks of the diet are needed
to obtain a 10% weight loss15.
To add to the concerns about the PSMF, it was
reported that the diet was suspected of causing severe
cardiac arrhythmias [19-23]. A loss of cardiac protein
content was supposed to be the mechanism the cardiac
complications [24]. Other researchers [19,25,26] attribu-
ted the effect to the low quality of protein used in the
PSMF, however the diet is thought to be safe for treat-
ments not longer than 10 days [22,23].
Around the time of the original report published by
Blackburn and colleagues, our Nutrition Unit at the Uni-
versity of Rome was using a PS diet (via 24 h IV infusion
of strictly amino acids, minerals and vitamins) on our
obese surgical patients. While the aim of our treatment
was to improve our surgical results, we also noted that
we confirmed Blackburn et al.’s findings with regards to
weight loss [27].
In the 1980s, when enteral nutrition took the place of
parenteral nutrition, we had the same results with a 24 h
enteral infusion of a solution of only proteins, electro-
lytes and vitamins. Those results were not published.Enteral protein sparing was generally used for obese
patients who needed nutritional support for postopera-
tive complications or acute pancreatitis. Obesity was
never the main indication for the enteral protein sparing
treatment. They were all hospitalized patients. Nitrogen
balance showed an acceptable level of nitrogen losses
and blood samples showed good tolerance of the treat-
ment with normal blood urea and electrolyte levels. No
cardiac complications were ever documented.
Six years ago the young, obese daughter of one of our
enteral protein sparing patients (with a postoperative
colon fistula) asked to be treated only for her obesity.
She underwent a home treatment and lost 15 kg of
weight. Since then, thousands of patients have come to
the University of Rome from all over Italy to be treated
and they had all heard of us only by word of mouth.
They signed a formal consent and were given a standard
apparatus for enteral nutrition (a small nasogastric tube
and a portable pump) for a 24 h infusion of protein to
be administered in cycles of 10 days.
In a preliminary study we found that the infusion of
50–65 g/day of high biological value protein (whey pro-
tein) caused a mild ketonemia (100–120 mg%), elimi-
nated hunger and greatly reduced the loss of lean body
mass while patients were losing weight rapidly. We
named this approach Ketogenic Enteral Nutrition
(KEN).
The aim of this study is to determine the feasibility of
KEN therapy for a large population of overweight or
obese patients and to assess its clinical results from a
retrospective analysis of the records of all patients who
underwent at least one cycle of KEN treatment. We also
wanted to compare the results from KEN treatment to
the results from other PSMF studies in which protein in-
take was given orally and was suspended during the
night. Long term results have been as well investigated.
Methods
The study was performed at the University La Sapienza
in Rome within the Clinical Nutrition Service (CNS) of
the Department of Surgery Paride Stefanini and included
overweight and obese patients who did not have success
with previous dietetic treatments for obesity.
Patients with type 1 diabetes, renal failure, heart fail-
ure, hepatic failure, history of severe cardiac arrhyth-
mias, severe eating disorders or who were pregnant or
lactating were excluded. Young patients under 14 were
included only if their body mass index (BMI) was over
40 and they had undergone a series of dietary treatments
without success. The patients were self-referred and
each patient had to sign an informed consent release be-
fore the beginning of the treatment. The procedures
were in accordance with the Helsinki Declaration of
1975 (as revised in 1983).
Figure 1 6-French polyurethane tubes are almost invisible and
very well tolerated.
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patients underwent at least one cycle of KEN treatment.
The patients’ ages varied from 10 to 78 (average
44.3 years). The male:female ratio was 2:5. The average
weight at the start of the treatment was 101.4 kg, and
was higher for men than women (118.9 kg vs 94.9 kg, re-
spectively). The mean BMI was 36.5 kg/m2 (in the limit
for class 1 and class 2 of obesity) and was also higher in
men than women (38.2 vs 35.8, respectively).
Each patient came to the CNS and received a medical
checkup before the beginning of treatment and a 50 Hz
impedance test for body composition analysis (Handy
3000; DS Medica, Italy). The body composition was cal-
culated by a computerized program which was provided
by the manufacturer, according to the three-
compartment model [28].
As shown in Table 1 at the start of the treatment men
had a very high body cell mass (BCM; 42.7 kg vs 27.4)
while the average fat mass (FM) was 40.9 kg and did not
differ between men and women (40.0 kg vs 41.7).
A 6-fr polyurethane tube was inserted through the
nose (Figure 1). The tube was held in place on the
patient’s cheek and ear by transparent tape.
The patients were given an enteral portable pump and
a short course to educate them about its use and about
the basics of KEN. The infusion rate was regulated to
provide, on a continuous, 24 h daily infusion, 2 l of fluid
and a dose of 50 g of protein (K1000W, Table 2) for
women and 65 g for men (resulting in an average dose
of 0.85 g/kg of ideal body weight in women and 0.89 g/kg
in men) and 13–17 mEq of potassium.
Each patient received, in addition, a supplement pro-
viding the RDA [29] for all vitamins and essential miner-
als. They were also given a 50 g dose of polyethylene
glycol to be taken on the first, fourth and seventh days
of treatment in order to increase intestinal motility and
to make up for the absence of fibers in the protein
solution.
The KEN cycles were domiciliary and a medical doctor
(MD) was available by telephone 24 h/day.Table 1 Patients’ baseline data before KEN (n = 19,036)
Total M F
Cases 19,036 5,148 13,888
Age 44.3 ± 13.0 44.7 ± 12.4 44.2 ± 13.2
Initial weight (kg) 101.4 ± 22.9 118.9 ± 22.9 94.9 ± 19.2
BMI (kg/m2) 36.5 ± 7.1 38.2 ± 6.8 35.8 ± 7.1
BCM (kg) 31.6 ± 8.7 42.7 ± 7.2 27.4 ± 4.6
FM (kg) 40.9 ± 12.8 40.0 ± 12.6 41.7 ± 12.8
TBW (kg) 43.5 ± 10.9 57.4 ± 9.2 38.3 ± 5.7
Table 1 shows the average age, weight and body composition of the patients
before the start of the KEN treatment. (BCM, body cell mass; FM, fat mass;
TBW, total body water).To ensure continuous ketosis during the treatment,
the patients had to stop feeding. They were allowed to
drink as much as they wanted, however they were only
allowed to drink water, tea, coffee and chamomile tea
without sweeteners.
During the cycle the patients were given a diary to
monitor weight, feeling of hunger (on a visual scale from










Table 2 Composition of K1000W (Nutrimed 2000 srl, Italy), the nutrition feed
used for the KEN, made of whey proteins enriched with potassium chloride,
lecithin and bovine hydrolyzed collagen.
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usual medication to avoid symptomatic hypotension that
was described by other authors during PSMF [30,31].
They had to monitor their blood pressure daily and con-
tact the MD in case of increased blood pressure.
As in other PSMF studies [32], diabetic patients were
asked to suspend their usual medications to avoid
hypoglycemia. They were also asked to monitor glycemia 3
times a day and to contact the MD in case of blood glucose
>160 mg%. Stopping or reducing the medications did not
cause any trouble, because KEN treatment rapidly reduces
hypertension and hyper-glycaemia. Many times we had to
discuss this matter with the physicians of our patients.
Patients affected by gout and/or hyperuricemia were
supplied with daily doses of allopurinol.
After each KEN cycle, patients returned to the CNS
for tube removal, to report all treatment data (including
daily evaluation of hunger level on a 1 to 10 visual scale,
body weight and ketonuria) and to undergo another im-
pedance test for body composition evaluation.
Each patient was free to choose the number of KEN
cycles he or she wanted to undergo. If the patient
wanted to undergo another treatment cycle they were
first given a rest period of at least 10 days during which
they were advised to follow a low–carbohydrate, normo-
caloric diet.
They were domiciliary patients and it was impossible
to schedule from the start of treatment the number of
cycles each patient had to undergo. We just told to each
patient his ideal body weight and informed him of the
risk of been obese or overweight.
All patients during the 5-year period of this study under-
went 1 to 21 cycles of KEN treatment (an average of 2.5 ±
0.03). The total duration of treatment time from the first
10-day KEN cycle to the last, including variable-length rest
periods (some patients came for a new cycle years later)
lasted from 9 to 1400 days (mean 68 ± 96).
Long term results data were collected by a telephone
survey which were assessed by nurses.
Results
Table 3 shows the final results. The male patients lost a
mean of 11.9 kg of weight which corresponded to 9.96%Table 3 Body Composition changes after treatment with KEN
t-test)
Weight and body composition changes after KEN treatment (n = 19,036
Total Variation ± SD M
Body weight (kg) 91.2 −10.2 ± 7.0* 107
BMI (kg/m2) 32.8 −3.7 ± 2.5* 34
BCM (kg) 29.4 −2.2* ± 3.3* 39
TBW (kg) 40.1 −3.4* ± 2.8* 52
FM (kg) 35.1 −5.8* ± 5.5* 34of initial body weight. Women also lost about 10% of
initial body weight.
The body composition analysis performed before and
after treatment showed that 57% of weight loss was
came from FM and 22% came from BCM.
No technical complications were reported during the
introduction of over 50,000 nasogastric tubes in a 5-year
period; neither were there any metabolic complications
due to ketonemia or electrolyte imbalances.
Ketonuria was observed in most patients by the 2nd
day of the KEN treatment and increased within 2–3 days
to 100–120 mg%. Commonly the ketonuria was accom-
panied by moderate halitosis, however this did not pre-
vent the patients from carrying out normal daily
activities.
By the 5th day of treatment 24% of patients reported a
strong sense of asthenia, even if they had normal blood
pressure levels. By the end of the treatment, 12% of
patients reported a mild sense of hunger.
Nearly one quarter (22%) of the patients were diabetic
and receiving treatment for their condition at the start
of treatment. As was observed by other authors [32],
92% of the diabetics in our study also had to suspend
their medications during the treatment periods because
the lack of carbohydrate in the nutritional solution was
sufficient to lower their glycaemia on its own. Of these
patients who suspended anti-diabetic therapy, 22%
reported glucose values as low as 60 mg/dL. However,
no cases of clinical hypoglycemia were reported neither
was glucose supplementation needed.
Reduced hypertension during PSMF has been reported
previously [30,31]. Similarly, in our study only 20% of
the hypertensive patients who had suspended their med-
ications during the treatments needed to resume their




2. Mild sense of hunger 12%
3. Constipation (need to increase
Macrogol) 5%
4. Problems with the pump 4%in male and female patients (*P < 0.0001. Student paired
)
Variation ± SD F Variation ± SD
.0 −11.9 ± 7.9* 85.4 −9.5 ± 6.5*
.3 −3.9 ± 2.6* 32.2 −3.6 ± 2.5*
.7 −3.0 ± 4.2* 25.6 −1.8 ± 2.8*
.7 −4.7 ± 3.5* 35.3 −3.0 ± 3.4*
.3 −5.7 ± 6.0* 35.9 −5.8 ± 5.2*
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(e.g. shaving) 2%
6. Gastric hypersecretion 2%
7. Nausea and vomiting 1%
8. Intolerance to the nasal tube 0.03%
9. Ulcerations or bleeding due to the tube not
observed
10. Breakage of the tube in esophagus or in the
stomach not observed
11. Perforation or bleeding of the stomach not observedLong term results
After the last KEN cycle (after 31–1882 days, average
408 ± 309 days) 15,444 patients could be reached by tele-
phone. We found that 55 patients had undergone baria-
tric surgery, which is not surprising since many patients
had been referred to us for preparation prior to bariatric
surgery because a preoperative loss of weight causes an
improvement of cardiovascular and thromboembolic risk
factors [33]. Regardless these individuals were excluded
from the survey. All the other patients had regained an
average of 1.57 ± 7.15 kg of body weight (15.4% of the
mean weight loss). 38.9% of patients presented a vari-
ation of ±3% and we can consider that they maintained
their weight loss, 36.9% gained weight (sometimes to a
value higher than the weight they had before the KEN
treatment) while 24.1% lost more weight because they
were able to return to their sporting activities.Discussion
It is insightful to compare the results of this study with
other PSMF studies in which protein was given by
mouth. In one study [15], weight loss after 17 weeks of
treatment was 21 kg versus 10.2 kg in 3.5 weeks in the
present study. Another smaller study [34] found results
are closer to ours: 15 patients lost 14.4 kg after 6 weeks
of PSMF with lactalbumin-derived protein dosed at
60 g/day. In a third study [35], patients lost around 8 kg
in 4 weeks on either a lean meat, fish, and fowl diet of
450 kcal or an isocaloric high-protein liquid diet. None
of the studies reported any significant clinical complica-
tions. The last study [35] found that the liquid formula
diet was less palatable than the whole food diet. In con-
trast we found that our patients were able to lose more
weight in less time, likely due to the fact that using a
24 h infusion we could further reduce protein (caloric)
intake while sparing lean mass.
The KEN diet is a well tolerated treatment that pro-
duces very rapid weight loss and gives the patient a psy-
chological boost because he/she sees immediate results.
This enthusiasm gives the patient the resolve to continue
with the treatment. Remember the thousands of patients
that came to us to undergo treatment were notresponding to any advertisements, rather they had heard
of us by word of mouth.
Another benefit of the KEN treatment is that it is a
low-cost treatment. Investments in the procedure in-
clude a 3-h course covering the principles of the treat-
ment to new patients, scales, stadiometers, impedance
apparati and pumps are relatively inexpensive. There-
fore, as all patients stop eating for 10 days, we can say to
them that the treatment will cost about the same
amount as eating their normal diet for 10 days.
A 6-fr nasogastric tube is very well tolerated; patients
get used to sensation within 10 minutes after insertion
and no longer feel its presence. Only a very small per-
centage of patients (0.03%) decided to stop treatment
when the tube was placed through the nose. In no cases
did the tube cause ulceration or bleeding, nor was there
any breakage in the esophagus or stomach. However, in
some cases the external part of the tube was damaged
by the patients themselves when trying to shave or when
trying to replace the tape using scissors. All these pro-
blems were solved by replacing the tube itself.
We have assumed that the nasal intubation and the
pump are essential to the success of our treatment for
controlling the intake of proteins during both day and
night and for reducing the catabolism of lean mass.
While this assumption should be tested in a double
blind study, our results still show that the KEN diet is
more effective in promoting weight loss than the PSMF
diet and reducing the length of treatment to 10 days pre-
vents the risk of cardiac complications [19-23].
Prof. Jay Mirtallo, President of the American Society
for Parenteral and Enteral Nutrition, recently wrote a
letter to the New York Times [36] about the nasogastric
tube for KEN treatment saying that “to report on some-
one using this medical therapy as a weight loss method
detracts from the health benefit achieved by patients
with very severe diseases”. We agree with him-- enteral
nutrition therapy is normally used to feed malnourished
patients who are unable to eat food by mouth for vari-
ous reasons (e.g. dysphagia, cancer) and its utilization
has a very important therapeutic value. However, in our
experience, extending the use of the nasal tube to obese
patients did not in any way impair the use of enteral
therapy in malnourished patients. To the contrary, in
Italy we noticed that, after thousands of patients began
asking for the therapy as a treatment for obesity, the
number of malnourished patients asking for the tube as
a life support doubled. We think this is likely because
they were able to observe how a high quality of life can
be maintained during the treatment, and that it is not a
big deal to have a small tube in your nose. Furthermore
we think the application of enteral therapy in the obese
opens new possibilities in healthcare, as worldwide there
are the millions of obese patients who could benefit
Cappello et al. Nutrition & Metabolism 2012, 9:96 Page 6 of 7
http://www.nutritionandmetabolism.com/content/9/1/96from this treatment, vastly outnumbering the thousands
of people with cancer or neurologic dysfunction that re-
quire a nasal tube.
With regard to the complications of KEN treatment
including asthenia and mild lightheadedness, which have
also been reported with the PSMF diet [15], the symp-
toms were easily relieved by increasing salt intake [15].
Gastric hypersecretion was present as acid reflux or
pyrosis in 2% of patients during KEN. This effect could
be due to the protein infusion [37,38] or it could be con-
nected with the mild metabolic acidosis [39] that occurs
in ketonemic diets [40]. Constipation is also commonly
reported during ketonemic diets [15,40], probably due to
the lack of fibers in the protein solution. This issue can
be resolved by increasing polyethylene glycol (PEG)
administration.
Nausea and vomiting has been reported also in an-
other study [15], and they are probably in response to
the gastric hypersecretion caused by the ketonemia or
by rapid intake of PEG. It is a rare complication but con-
cerning because it can lead to expulsion of the nasal
tube which then has to be re-inserted.
KEN treatment is not an option for long-term dieting
because it contains 0% carbohydrates and 0% lipids. Ra-
ther, KEN is suitable as a 10-day controlled period of
starvation during which the protein sparing effect of the
continuous infusion of protein allows a fast and safe re-
duction of weight. Although the weight loss is still 22%
BCM, this is to be expected given that the obese and
overweight patients show elevated BCM before the start
of treatment. This has been confirmed by other authors
[41] and a minor loss of BCM is not significant. In future
studies we will modulate the protein infusion with respect
to the impedance analysis in the aim of reducing BCM
loss and of increasing FM loss from their current levels.
Losing 4 kg of fat mass means burning 36,000 calories
in 10 days. In other words, to lose 1 kg of fat an individ-
ual would need to walk for 75 km42. We tell our
patients to live an active life, to maintain their normal
daily activities in spite of the presence of the nasal tube
and to walk at least one hour per day (if they can). This
probably is not enough to burn all those calories. But we
must take into account other outputs, such as the loss of
ketones in the urine, in the breath and in the sweat; that
is, during ketosis there is some insensible loss of calories.
Furthermore protein infusions are reported to increase en-
ergy expenditure by increasing thermogenesis [42-44].
The long term results from our study were very posi-
tive. The data were collected by a telephone survey, and
while we could not check the patients’ weights directly,
we feel the self-reported body weights are accurate and
other reports on long term results after weight loss
treatments are also based on telephone surveys [45]. At
the end of a patient’s final KEN cycle they were advisedto regularly check their body weight and were given ad-
vice on how to reduce their weight again if it began to
go back up. They were also advised to consult an MD as
needed, however it was rare that they asked for help. In
our study we observed a 15.4% weight regain after one
year, which is an excellent result if we compare it with
other reviews in which a 30-35% weight regain after one
year is reported [45]. This difference may be because
KEN treatment spares free fat mass, and this reduces
weight regain [46]. Furthermore the initial weight of our
patients was higher than in most weight maintenance
studies [47] which may also account for our improved
long-term results [48,49].
Weight loss in our diabetic and hypertensive patients
also promoted long-term improvement to their condi-
tions, as has been reported in another study [50], and
these results will be the subject of a separate report.
Limitations of this study are related to (1) the lack of a
control group, which would be impossible to obtain in
our settings. (2) We could not plan the treatment of
each patient at the start because they were on domicil-
iary treatment and (3) many patients come back for a
new cycle after years of rest making uncertain the evalu-
ation of their overall clinical outcome.”
Conclusions
During the course of 5 years nearly 50,000 small 6-
French nasogastric tubes were inserted without compli-
cations and they were well tolerated by our patients.
This study demonstrates that 10-day KEN cycles can in-
duce rapid weight loss; in a very large number of
patients we easily obtained a 10% weight loss, 57% of
which was FM. No significant adverse effects were
found. On a 1-month/5-year follow up, mean weight re-
gain was 15.4%. The KEN cycles are suitable for normal
living and the cost is minimal, indeed some patients
spend less on the treatment than they would spend on
10 days worth of food. Ultimately we conclude that KEN
treatment is safe, fast, inexpensive and has good one-
year results for weight maintenance. We propose that
KEN is a new approach to obesity treatment which is
faster and more effective than hypocaloric diets [47],
without the complications of bariatric surgery.
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Clinical relevancy statement
Dieters of 21st century want instant weight loss and do not want to lose
“only” a few pounds each week. Finding a fast and safe weight loss
treatment could be the crucial battle to win in the war on obesity. Ketogenic
Enteral Nutrition is a modified approach that allows a fast weight loss. It was
tested on thousands of patients and it turned out to be safe and
inexpensive, we can say to our patients that the treatment will cost about
the same amount as eating their normal diet for 10 days.
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